110 related articles for article (PubMed ID: 10637251)
1. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Bishop MC; Perkins AC; Wastie ML; Denton G; Price MR; Frier M; Denley H; Rutherford R; Schubiger PA
J Clin Oncol; 2000 Jan; 18(2):363-70. PubMed ID: 10637251
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer.
Hughes OD; Bishop MC; Perkins AC; Frier M; Price MR; Denton G; Smith A; Rutherford R; Schubiger PA
Eur J Nucl Med; 1997 Apr; 24(4):439-43. PubMed ID: 9096097
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.
Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC
J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567
[TBL] [Abstract][Full Text] [Related]
4. Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer.
Syrigos KN; Khawaja M; Krausz T; Williams G; Epenetos AA
Acta Oncol; 1999; 38(3):379-82. PubMed ID: 10380831
[TBL] [Abstract][Full Text] [Related]
5. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
6. Targeting of bladder cancer with monoclonal antibody NCRC48--a possible approach for intravesical therapy.
Kunkler RB; Bishop MC; Green DJ; Pimm MV; Price MR; Frier M
Br J Urol; 1995 Jul; 76(1):81-6. PubMed ID: 7648066
[TBL] [Abstract][Full Text] [Related]
7. Intravesical administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma.
Bamias A; Keane P; Krausz T; Williams G; Epenetos AA
Cancer Res; 1991 Jan; 51(2):724-8. PubMed ID: 1985790
[TBL] [Abstract][Full Text] [Related]
8. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
[TBL] [Abstract][Full Text] [Related]
9. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer.
Chiou RK; Dalrymple GV; Baranowska-Kortylewicz J; Holdeman KP; Schneiderman MH; Harrison KA; Taylor RJ
J Urol; 1999 Jul; 162(1):58-62. PubMed ID: 10379740
[TBL] [Abstract][Full Text] [Related]
10. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Perkins AC; Frier M; Wastie ML; Denton G; Price MR; Denley H; Bishop MC
BJU Int; 2001 Jan; 87(1):39-46. PubMed ID: 11121991
[TBL] [Abstract][Full Text] [Related]
11. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas.
Bamias A; Bowles MJ; Krausz T; Williams G; Epenetos AA
Int J Cancer; 1993 Jul; 54(6):899-903. PubMed ID: 8335396
[TBL] [Abstract][Full Text] [Related]
12. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
13. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
Frier M
Mini Rev Med Chem; 2004 Jan; 4(1):61-8. PubMed ID: 14754444
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Russell PJ; Davis K; Kingsley E; Humphreys J; Hanley J; O'Grady H; Pearce N
Cell Biophys; 1994; 24-25():155-61. PubMed ID: 7736520
[TBL] [Abstract][Full Text] [Related]
15. Immunolocalization of transitional cell carcinoma of the bladder with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody.
Malamitsi J; Zorzos J; Varvarigou AD; Archimandritis S; Dassiou C; Skarlos DV; Dimitriou P; Likourinas M; Zizi A; Proukakis C
Eur J Nucl Med; 1995 Jan; 22(1):25-31. PubMed ID: 7698151
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
[TBL] [Abstract][Full Text] [Related]
17. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer.
Simms MS; Murray A; Denton G; Scholfield DP; Price MR; Perkins AC; Bishop MC
Urol Res; 2001 Feb; 29(1):13-9. PubMed ID: 11310209
[TBL] [Abstract][Full Text] [Related]
18. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
19. Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.
Fazel J; Rötzer S; Seidl C; Feuerecker B; Autenrieth M; Weirich G; Bruchertseifer F; Morgenstern A; Senekowitsch-Schmidtke R
Cancer Biol Ther; 2015; 16(10):1526-34. PubMed ID: 26177233
[TBL] [Abstract][Full Text] [Related]
20. Copper-67 as a therapeutic nuclide for radioimmunotherapy.
Novak-Hofer I; Schubiger PA
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):821-30. PubMed ID: 12029558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
